Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic
syndrome; its rising prevalence parallels the rise in obesity and diabetes. Historically …

Nonalcoholic steatohepatitis (NASH), a chronic liver disease without an approved therapy, is
associated with lipotoxicity and insulin resistance and is a major cause of cirrhosis and …

Increased fructose consumption has been suggested to contribute to non-alcoholic fatty liver
disease (NAFLD), dyslipidemia, and insulin resistance, but a causal role of fructose in these …

Excessive caloric intake in a form of high-fat diet (HFD) was long thought to be the major risk
factor for development of obesity and its complications, such as fatty liver disease and …

A key and highly regulated enzyme that is required for the biosynthesis of monounsaturated
fatty acids is stearoyl-CoA desaturase (SCD), which catalyzes the D9-cis desaturation of a …

Obesity and type 2 diabetes are occurring at epidemic rates in the United States and many
parts of the world. The" obesity epidemic" appears to have emerged largely from changes in …

Dietary carbohydrates regulate hepatic lipogenesis by controlling the expression of critical
enzymes in glycolytic and lipogenic pathways. We found that the transcription factor XBP1, a …

Fatty acid synthase (FAS) catalyzes the de novo synthesis of fatty acids. In the liver, FAS has
long been categorized as a housekeeping protein, producing fat for storage of energy when …

Nonalcoholic fatty liver disease (NAFLD) is associated with all features of the metabolic
syndrome. Although deposition of excess triglycerides within liver cells, a hallmark of …